Françoise Boyer‐Perrard

Author

Also Known As

Boyer-Perrard F, Francoise Boyer-Perrard, Françoise Boyer-Perrard, Françoise Boyer, Françoise Boyer-Perrard, Françoise Boyer‐Perrard

Publications

264

Citations

H-Index

Concepts

All Affiliations

Françoise Boyer‐Perrard is an author at Centre Hospitalier Universitaire d'Angers specializing in oncology, transplantation, and tumor biology.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	20
2	Cell Biology	1	1	20
3	Pathology	1	1	20
4	Hematology	1	1	20
5	Transplantation	1	1	20

Françoise Boyer‐Perrard

Publications

234

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the <scp>FIM</scp> and <scp>GEM</scp> French cooperative groups Jean‐Christophe Ianotto, Françoise Boyer‐Perrard, Emmanuel Gyan, British Journal of Haematology	2013	78
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study Jean‐Christophe Ianotto, Aurélie Chauveau, Françoise Boyer‐Perrard, Haematologica	2017	64
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis Alessandro M. Vannucchi, Peter A.W. te Boekhorst, Claire Harrison, Haematologica	2018	46
Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis Jean‐Jacques Kiladjian, Juliette Soret‐Dulphy, Matthieu Resche‐Rigon, Blood	2018	26
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase Lise-Marie Mollard, Aurélie Chauveau, Françoise Boyer‐Perrard, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyTransplantationElderly PatientsMedicineMixed-phenotype Acute Leukemia	2018	20

Page 1